Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05351749 · ClinicalTrials.gov registry record · NA
Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use
A NA study of Atrial Fibrillation and Pulmonary Embolism, sponsored by University of Michigan.
- Active
- Registry status
- NA
- Development phase
- 306
- Enrollment target
- 1
- Study location
NCT05351749 is a NA study of Atrial Fibrillation and Pulmonary Embolism that is active but no longer recruiting, run by University of Michigan. The registered enrollment target is 306 participants, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05351749, a NA study of Atrial Fibrillation and Pulmonary Embolism, is active but no longer recruiting, sponsored by University of Michigan.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 306 participants
- Enrollment target
- 1
- Study location
Study Summary
The researchers hypothesize that existing-prescription notifications directed to pharmacists are more likely to lead to a prescription change than existing-prescription notifications directed to prescribers. Furthermore, the researchers hypothesize that the availability of a pharmacist referral option is associated with a higher rate of prescription changes for initial-prescription alerts that are directed to the prescriber at the time of initial-prescribing errors. Findings from this project will establish a framework for implementing prescriber-pharmacist collaboration for high risk medications, including anticoagulants
Conditions Studied
Interventions
- BEHAVIORAL New-prescription Alert
- BEHAVIORAL New-prescription Alert with referral option
- BEHAVIORAL Existing-prescription notification to prescriber
- BEHAVIORAL Existing-prescription notification to pharmacist
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 306 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2026-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05351749
The ClinicalTrials.gov registry entry for NCT05351749 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 306 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (90% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 4 interventions - of which New-prescription Alert is the first listed.
NCT05351749 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT05351749 about?
NCT05351749 is a clinical study titled "Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use". The researchers hypothesize that existing-prescription notifications directed to pharmacists are more likely to lead to a prescription change than existing-prescription notifications directed to prescribers. Furthermore, the researchers hypothesize that the availability of a pharmacist referral opti...
What is the current status of trial NCT05351749?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 306 participants. The study started on 2022-08-01. Estimated completion is 2026-01.
What conditions does trial NCT05351749 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Pulmonary Embolism, Venous Thromboembolism.
What interventions are being tested in trial NCT05351749?
The interventions under investigation include: New-prescription Alert (BEHAVIORAL), New-prescription Alert with referral option (BEHAVIORAL), Existing-prescription notification to prescriber (BEHAVIORAL), Existing-prescription notification to pharmacist (BEHAVIORAL).
Who is sponsoring clinical trial NCT05351749?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05351749 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
-
The CONFORM Pivotal Trial
RECRUITING · NA
-
Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study
RECRUITING · NA
-
The Fourth Left Atrial Appendage Occlusion Study
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.